GLP-1/GIP Dual Bias: Evolution Of Long-acting Formulations

Thaum Lub Ob Hlis 16, 2026, Shiyao Group tshaj tawm tias nws GLP-1/GIP receptor dual directional agonist peptide ntev-kev txhaj tshuaj (SYH2082 txhaj) tau pom zoo los ntawm US Food and Drug Administration (FDA) rau kev sim tshuaj hauv Tebchaws Meskas. SYH2082 xav tias yuav dhau los ua qhov ntev - ua haujlwm GLP-1 / GIP receptor dual biased agonist nrog kev muaj peev xwm ua tau zoo hauv kev kho mob, ua haujlwm ib hlis ib zaug. Kev vam khom rau peb pab pawg cov txheej txheem kev ua haujlwm ntev, SYH2082 ua tiav kev tswj hwm txhua hli, txhim kho kev ua raws li tus neeg mob thiab kev siv tshuaj yooj yim.

SYH2082 tuaj yeem xaiv txoj hauv kev cAMP, txo B-arfestin recruitment, yog li txo cov receptor endocytosis thiab desensitization, txhim kho cov tshuaj siv tau zoo thiab ua kom lub sijhawm ua haujlwm ntev. Lub caij no, SYH2082 sib xyaw ua ke ntev ib nrab- lub neej hloov kho platform thev naus laus zis thiab ntev - ua qauv txheej txheem thev naus laus zis kom ua tiav qhov hnyav poob hauv lub sijhawm noj. Hauv kev tshawb fawb preclinical, SVH2082 tau pom tias muaj txiaj ntsig zoo nyob rau hauv ntev - poob phaus thiab kev saib xyuas piv rau cov khoom lag luam zoo sib xws, thiab txhawb nqa cov tshuaj noj txhua hli. Hauv kev tshawb fawb toxicology, SYH2082 muaj qhov ua tau zoo thiab tsis muaj qhov cuam tshuam loj heev tau pom.

Semaglutide hmoov CAS 910463-68-2

1.Peb muab
(1) Tablet
(2) Cov
(3) Capsule
(4) Txau
(5) API (Ntshiab hmoov)
(6) Pill press machine
https://www.achievechem.com/pill-xwm
2.Customization:
Peb yuav sib tham tus kheej, OEM / ODM, Tsis muaj hom, rau kev tshawb nrhiav kev ruaj ntseg nkaus xwb.
PIB: BM-2-4-008
Semaglutide CAS 910463-68-2
Kev tshuaj xyuas: HPLC, LC-MS, HNMR
Kev them nyiaj yug Technology: R&D Dept.-4

Peb muab Semaglutide Powder, thov xa mus rau lub vev xaib hauv qab no kom paub meej cov lus qhia thiab cov khoom lag luam.

Khoom siv:https://www.bloomtechz.com/synthetic-chemical/peptide/semaglutide-powder-cas-910463-68-2.html

Thaum Lub Ob Hlis 17, 2026, Novo Nordisk tshaj tawm tias nws daim ntawv thov kev lag luam rau 7.2mg semaglutide rau kev tswj qhov hnyav tau pom zoo los ntawm European Medicines Agency (EMA).

Qhov kev pom zoo no yog ua raws li cov txiaj ntsig zoo ntawm Kev Kawm Phaj II STEP UP thiab Theem III STEP UPT2D txoj kev kawm.
Txoj kev tshawb fawb STEPUP tau pom tias nyob rau hauv cov neeg laus rog rog yam tsis muaj ntshav qab zib, tom qab 72 lub lis piam ntawm kev kho mob, cov nyhuv poob ntawm 7.2mg smeglutide pawg tau zoo dua li ntawm pawg placebo, nrog qhov sib txawv tseem ceeb. Qhov nruab nrab qhov hnyav ntawm cov neeg kawm yog 113kg.

Raws li kev tshuaj xyuas ua tiav, qhov poob phaus hauv 7.2mg, 2.4mg semaglutide pawg thiab placebo pawg yog 20.7%, 6%, 17.5%, thiab 2.4%, feem. Ntawm lawv, 33.2% ntawm cov neeg mob hauv pawg 7.2mg poob ntau dua 25% qhov hnyav, 16.7% hauv pawg 2.4mg, thiab 0.0% hauv pawg placebo; Lub hom phiaj los kho cov txiaj ntsig kev soj ntsuam tau pom tias qhov poob ntawm peb pawg yog 18.7%, 15.6%, thiab 3.9%, feem.
Hais txog kev nyab xeeb, 7.2mg semaglutide qhia tau hais tias muaj kev nyab xeeb zoo thiab kev zam rau hauv txoj kev tshawb no. Cov xwm txheej tsis zoo tshwm sim feem ntau yog cov xwm txheej tsis zoo hauv plab hnyuv, feem ntau ntawm cov mob me me mus rau nruab nrab thiab txo qis rau lub sijhawm, ua raws li cov yam ntxwv ntawm GLP-1 receptor agonists hauv kev tshawb fawb yav dhau los.

Thaum Lub Ob Hlis 18, 2026, Huadong Pharmaceutical's GLP-1R / GIPR agonist HDM1005 tau pib nws thawj lub taub hau mus rau lub taub hau theem kuv kuaj mob.

Qhov kev tshawb fawb theem pib lub sijhawm no yog ntau qhov chaw, randomized, qhib daim ntawv lo, tshuaj zoo tswj kev soj ntsuam kuaj mob (=912), uas yog lub hom phiaj los ntsuas kev ua tau zoo thiab kev nyab xeeb ntawm HDM1005 (subcutaneous txhaj, ib zaug ib lub lis piam) piv rau Masidotide (subcutaneous txhaj, ib zaug hauv ib lub lis piam) hauv kev kho mob ntshav qab zib hom 2 nrog cov neeg mob ntshav qab zib hom 2. SGLT2 inhibitor. Lub ntsiab lus kawg ntawm txoj kev tshawb no yog kev hloov pauv hauv glycated hemoglobin (HbAlc) qib los ntawm cov hauv paus.

HDM1005 (poterepatide) yog peptide raws li tib neeg GLP-1R/GIPR dual lub hom phiaj ntev- ua yeeb yam agonist tsim los ntawm Huadong Pharmaceutical lub tuam txhab, Zhongmei Huadong. Cov kev tshawb fawb ua ntej tau pom tias HDM1005 tuaj yeem qhib GLP-IR thiab GIPR, txhawb kev tsim cov cyclic adenosine monophosphate (CAMP), ua rau cov kab mob pancreatic secretion, suppress qab los noj mov, qeeb plab hnyuv plab, txhim kho cov metabolism hauv, yog li txhim kho cov ntshav ntim, txo cov oxidative kev nyuaj siab thiab cov kab mob plawv, thiab ua kom cov kab mob plawv. Nws muaj cov txiaj ntsig ntawm kev txo cov ntshav qab zib, txo qhov hnyav, txhim kho MASH, thiab khaws cia ejection feem hauv plawv tsis ua hauj lwm (HFpEF). Lub caij no, cov ntaub ntawv uas twb muaj lawm qhia tau hais tias HDM1005 muaj qhov ua tau zoo ntawm qhov hnyav, kev nyab xeeb zoo thiab kev ua haujlwm ntev.